Drug Trial Radar · NCT04971291
An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
Last checked: Nov 19, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
312
Planned (sponsor's estimate)
Start
Apr 14, 2021
Primary completion
Jul 2021
Study completion Jul 2021
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug. Subjects are considered to have treatment-resistant MDD if they have had a historical inadequate response to 1 or 2 prior antidepressant treatments (ADTs) and a prospective inadequate response to treatment with bupropion SR, during the current major depressive episode. The TARGET study will first determine treatment adherence based on analysis of drug concentrations of dextromethorphan (in the AXS-05 group) and bupropion (in the bupropion group), and then evaluate the efficacy of AXS-05 in patients determined to be treatment-adherent. Efficacy data for evaluation of treatment effect will be obtained from assessments made during study AXS-05-301.
Conditions
- Major Depressive Disorder
- Treatment Resistant Depression
Interventions
AXS-05Drug
AXS-05 taken twice daily for 6 weeks
Bupropion SRDrug
Bupropion taken twice daily for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Åsberg Depression Rating Scale (MADRS) total scoreTime frame: Change from Baseline to Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Axsome Research Site
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.